Vicor R&D increased by 8.5% to $22.29M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.0%, from $19.38M to $22.29M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 10.3% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.27M | $13.52M | $13.30M | $14.25M | $15.52M | $14.75M | $16.08M | $15.87M | $16.94M | $17.75M | $17.30M | $18.04M | $16.94M | $16.96M | $16.98M | $19.38M | $18.79M | $19.86M | $20.54M | $22.29M |
| QoQ Change | — | +1.9% | -1.6% | +7.2% | +8.9% | -5.0% | +9.0% | -1.3% | +6.7% | +4.8% | -2.5% | +4.3% | -6.1% | +0.1% | +0.1% | +14.1% | -3.0% | +5.7% | +3.4% | +8.5% |
| YoY Change | — | — | — | — | +16.9% | +9.1% | +20.9% | +11.3% | +9.1% | +20.4% | +7.6% | +13.7% | +0.0% | -4.5% | -1.8% | +7.4% | +10.9% | +17.1% | +21.0% | +15.0% |